PATENT CLAIM ANALYSIS

Application Number: 16295536
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["424", "133100"]

Abstract:
Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

Claim (Index 22):
The method of  claim 19 , wherein the measuring comprises amplifying one or more of SLC8A3, VNN2, BEST2, CCL2, CCL3, CCL3L1/3, CPA3, FGF7, HAMP, IL1A, IL18RAP, INHBA, LIF, LMO4, LRRC4, MLK7.AS1, MT1M, MUCL1, MX1, PMCH, REM2, SSTR2, TM4SF4, TMEM154, UROS, and VNN3 mRNA and detecting the amplified mRNA, thereby measuring the level of the amplified mRNA.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 99.0
- Lexical Diversity: 1.84615
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15271687', '14675081', '13348709', '12390730', '11219121']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7104665707667926
- 35 USC 102 Novelty (BERT): 0.7736684749909545
- Combined Prediction Score: 0.7167867611892089
- Mean Citation Score: 470.705118
- Max Citation Score: 938.87976
- Similarity Product: 895.8295125970744

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test